Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy.

Autor: Goldschmidt J; Blue Ridge Cancer Centers/US Oncology Research, Blacksburg, VA, USA., Hart L; Florida Cancer Specialists & Research Institute, Fort Myers, FL, USA., Scott J; Integra Connect, West Palm Beach, FL, USA., Boykin K; Florida Cancer Specialists & Research Institute, Fort Myers, FL, USA., Bailey R; Florida Cancer Specialists & Research Institute, Fort Myers, FL, USA., Heritage T; Florida Cancer Specialists & Research Institute, Fort Myers, FL, USA., Lopez-Gonzalez L; G1 Therapeutics, Inc., Research Triangle Park, NC, USA., Zhou ZY; Analysis Group Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA., Edwards ML; Analysis Group Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA. MarieLouise.Edwards@analysisgroup.com., Monnette A; Ontada, Woodlands, TX, USA., Ogbonnaya A; Xcenda, Carrolton, TX, USA., Deyoung K; Xcenda, Carrolton, TX, USA., Venkatasetty D; Ontada, Woodlands, TX, USA., Shi P; Ontada, Woodlands, TX, USA., Aton L; Integra Connect, West Palm Beach, FL, USA., Huang H; G1 Therapeutics, Inc., Research Triangle Park, NC, USA., Conkling PR; Ontada, Woodlands, TX, USA., Gordan L; Florida Cancer Specialists & Research Institute, Fort Myers, FL, USA.
Jazyk: angličtina
Zdroj: Advances in therapy [Adv Ther] 2023 Oct; Vol. 40 (10), pp. 4189-4215. Date of Electronic Publication: 2023 Jul 25.
DOI: 10.1007/s12325-023-02601-2
Abstrakt: Introduction: Trilaciclib was recently approved in the USA for reducing chemotherapy-induced myelosuppression (CIM) among adults with extensive-stage small cell lung cancer (ES-SCLC) when administered prior to chemotherapy. There is limited understanding of real-world outcomes of trilaciclib.
Methods: A comprehensive literature review was conducted using a keyword search in the MEDLINE, Embase, and conference abstracts. Additional studies were identified through communications with the authors of relevant studies. Published and unpublished real-world studies of trilaciclib- and comparable non-trilaciclib-treated patients with ES-SCLC were included. Evidence on myelosuppressive hematologic adverse events (HAEs), cytopenia-related healthcare utilization, and other reported outcomes (e.g., hospitalizations, dose reduction, and treatment delay) were synthesized. If feasible, outcomes were compared qualitatively between the trilaciclib and historical reference groups, and between first-line trilaciclib initiators and the overall trilaciclib population. Weighted averages were estimated for selected outcomes using sample size as the weight.
Results: The literature search identified five unique studies based on eight records-two included trilaciclib only, two non-trilaciclib only, and one both. In trilaciclib cohorts, the weighted average prevalence of grade ≥ 3 myelosuppressive HAEs in ≥ 1 lineage, ≥ 2 lineages, and all three lineages was 40.5%, 14.5%, and 7.5%, respectively. All rates were numerically lower compared to the historical non-trilaciclib cohorts (58.8%, 28.0%, 13.0% respectively). Cytopenia-related healthcare utilization was also lower in the trilaciclib cohorts. In general, first-line trilaciclib initiators had numerically lower myelosuppressive HAEs and cytopenia-related healthcare utilization than the overall trilaciclib patients.
Conclusions: The existing evidence suggests that trilaciclib may reduce single and multilineage grade ≥ 3 myelosuppressive HAEs and cytopenia-related healthcare utilization among patients with ES-SCLC in the real world. It is a promising new treatment for CIM prevention in ES-SCLC and may bring greater benefits to first-line trilaciclib initiators. Future studies are recommended to further evaluate the real-world effectiveness of trilaciclib.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: